FOLD · As filed with the SEC

Amicus Therapeutics cash flow statement, by quarter

The statement as Amicus Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Statements of Cash Flows · USD thousands

USD thousands	Q4 2025^† 3 months ended Dec 31, 2025	Q3 2025^† 3 months ended Sep 30, 2025	Q2 2025^† 3 months ended Jun 30, 2025	Q1 2025 3 months ended Mar 31, 2025
Operating activities
Net loss	1,690^†	17,306^†	(24,420)^†	(21,686)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount and deferred financing	676^†	658^†	630^†	606
Depreciation and amortization	1,897^†	1,874^†	1,852^†	1,837
Stock-based compensation	26,590^†	18,089^†	17,559^†	25,172
Foreign currency remeasurement loss	(3,622)^†	8,453^†	4,111^†	(5,356)
Other	—	(835)^†	2,794^†	1,175
Changes in operating assets and liabilities:
Accounts receivable	(614)^†	(8,084)^†	(12,492)^†	15,330
Inventories	(44,296)^†	(36,322)^†	(22,577)^†	(8,288)
Prepaid expenses and other current assets	(595)^†	7,570^†	(4,754)^†	(3,603)
Accounts payable, accrued expenses, and other current liabilities	38,143^†	30,627^†	10,360^†	3,647
Other non-current assets and liabilities	656^†	(3,676)^†	411^†	(1,076)
Net cash provided by (used in) operating activities	16,253^†	35,660^†	(26,526)^†	7,758
Investing activities
Sale and redemption of marketable securities	16,857^†	17,256^†	10,995^†	6,161
Purchases of marketable securities	(23,052)^†	(18,173)^†	(14,370)^†	(38,810)
Capital expenditures	(299)^†	(382)^†	(2,403)^†	(212)
Net cash (used in) provided by investing activities	(6,494)^†	(1,299)^†	(5,778)^†	(32,861)
Financing activities
Withholding taxes paid on vested restricted stock units	(4,460)^†	(1,641)^†	(432)^†	(11,790)
Proceeds from stock options exercised, net	18,721^†	339^†	40^†	105
Payment of finance leases	(232)^†	(17)^†	(8)^†	(15)
Net cash provided by financing activities	14,029^†	(1,319)^†	(400)^†	(11,700)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash	(329)^†	(1,200)^†	9,987^†	4,819
Net increase (decrease) in cash, cash equivalents, and restricted cash	23,459^†	31,842^†	(22,717)^†	(31,984)
Cash, cash equivalents, and restricted cash at the beginning of the year	193,857	162,015	184,732	216,716
Cash, cash equivalents, and restricted cash at the end of the year	217,316	193,857	162,015	184,732
Supplemental disclosures of cash flow information
Tenant improvements paid through lease incentive	98^†	97^†	98^†	97
Cash paid during the period for interest	10,756^†	11,058^†	10,942^†	10,852
Cashless exercise of warrants	0^†	0^†	0^†	71
Capital expenditures unpaid at the end of period	73^†	(174)^†	36^†	138
Cash paid for income taxes	12,549^†	1,614^†	354^†	377

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.